Updated:
Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology, led by CEO Jerry He, is a Nasdaq-listed biotech spinning out organ regeneration technology from Harvard...
Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology was incorporated in 2012 as a spinout from Harvard Bioscience, taking the parent company's syringe-pump and bioreactor apparatus expertise and aiming it at a single clinical target: the trachea. The firm operates as a publicly traded regenerative-medicine company rather than a traditional family office or private investment vehicle, listing on Nasdaq under the ticker HRGN. Its founding thesis rests on seeding a synthetic scaffold with a patient's own cells to grow a replacement airway, then implanting it to repair otherwise fatal tracheal damage. The company's research centers on a proprietary bioreactor system combined with a decellularized synthetic scaffold. It has pursued clinical cases primarily outside the United States, with regulatory filings and compassionate-use implants reported in Russia and other regions. The strategy does not deploy capital across asset classes or stages; nearly all resources flow into a single-device regulatory pathway. No fund commitments, SPVs, or co-investment clubs are part of the model. The firm has disclosed clinical implants in a small number of patients and reported follow-up data at thoracic-surgery conferences. With a market capitalization historically below $50 million, the firm maintains minimal operating infrastructure in Holliston, Massachusetts. Jerry He serves as CEO while Junli He holds the chairman role. The board has cycled through multiple strategic reviews, and the firm has periodically explored reverse-merger targets and platform acquisitions to broaden its device pipeline beyond the airway. Its Nasdaq listing makes it an unusual hybrid: a development-stage biotech funded by public shareholders rather than venture capital. The structural differentiator is its public-company chassis for a pre-revenue medical device. While most regenerative-medicine enterprises stay private or partner with large strategics, HRGN has used registered direct offerings and convertible instruments to fund successive clinical milestones entirely within the public eye. That architecture imposes short-term disclosure and investor-relations overhead that peer projects in academic labs or VC-backed startups avoid, creating a distinct operating discipline that shapes every regulatory filing and shareholder communication.
General information
Firm type
Asset Manager
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Holliston
Corporate office
Holliston, MA, United States
Principals
Jerry He
Chief Executive Officer
Junli He
Chairman
Sector focus
Frequently asked questions
Is Harvard Apparatus Regenerative Technology a family office or an operating company?
It is an operating company and a publicly traded one, not a family office. The firm develops a single-device platform for tracheal regeneration and funds itself through public-market equity and convertible offerings rather than through a private family's balance sheet. Its Nasdaq listing under ticker HRGN obligates quarterly SEC reporting and public shareholder governance.
What clinical problem does the company's core technology target?
The firm targets end-stage tracheal disease — conditions where a patient's airway is so damaged that mechanical ventilation or standard surgical reconstruction is insufficient. Its approach implants a synthetic scaffold seeded with the patient's own cells, grown in a proprietary bioreactor, with the aim of forming a living, functional replacement. Early compassionate-use procedures were conducted outside the United States, as reported in thoracic-surgery literature.
How does Harvard Apparatus Regenerative Technology fund its research?
Unlike most pre-revenue biotechs that rely on venture capital, HRGN accesses public markets directly through registered direct offerings, at-the-market facilities, and convertible note financings. The firm has no single large private backer and no committed fund structure — its balance sheet is sustained by periodic equity raises disclosed in SEC filings.
Who are the key executives and directors?
Jerry He serves as Chief Executive Officer and has led the company through multiple clinical and strategic pivots. Junli He is the Chairman of the board. The board and officer roster has shifted over time, and current composition is disclosed in the firm's annual proxy statements and 10-K filings with the SEC.
What regulatory approvals has the technology received?
The device has not received FDA approval in the United States as of the most recent public disclosures. Clinical activity has centered on compassionate-use implants in overseas jurisdictions, with the firm presenting case reports and follow-up data at international medical meetings to support eventual regulatory submissions.
Does the firm invest in outside startups or other biotech companies?
No. Harvard Apparatus Regenerative Technology is a single-product development company, not an investment vehicle. Its capital expenditures go entirely into internal R&D, regulatory consulting, manufacturing scale-up, and the public-company costs of being Nasdaq-listed.
What is the relationship between Harvard Apparatus Regenerative Technology and Harvard University?
Despite the name, the firm is not affiliated with Harvard University or its endowment. The 'Harvard Apparatus' lineage traces to Harvard Bioscience, a public laboratory-equipment company from which HRGN was spun out in 2012–2013. The branding reflects the parent company's historic name, not an academic or university relationship.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: